Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Other financing activities (2019 - 2023)

Historic Other financing activities for Beam Therapeutics (BEAM) over the last 5 years, with Q3 2023 value amounting to $384000.0.

  • Beam Therapeutics' Other financing activities rose 143600.0% to $384000.0 in Q3 2023 from the same period last year, while for Dec 2023 it was $631000.0, marking a year-over-year increase of 23563.83%. This contributed to the annual value of $631000.0 for FY2023, which is 23563.83% up from last year.
  • Beam Therapeutics' Other financing activities amounted to $384000.0 in Q3 2023, which was up 143600.0% from $185000.0 recorded in Q2 2023.
  • In the past 5 years, Beam Therapeutics' Other financing activities ranged from a high of $8.0 million in Q1 2021 and a low of $6000.0 during Q1 2022
  • For the 5-year period, Beam Therapeutics' Other financing activities averaged around $832176.5, with its median value being $209000.0 (2021).
  • Per our database at Business Quant, Beam Therapeutics' Other financing activities plummeted by 9992.46% in 2022 and then soared by 143600.0% in 2023.
  • Quarter analysis of 5 years shows Beam Therapeutics' Other financing activities stood at $1.4 million in 2019, then crashed by 76.13% to $342000.0 in 2020, then plummeted by 62.57% to $128000.0 in 2021, then tumbled by 57.81% to $54000.0 in 2022, then skyrocketed by 611.11% to $384000.0 in 2023.
  • Its Other financing activities was $384000.0 in Q3 2023, compared to $185000.0 in Q2 2023 and $62000.0 in Q1 2023.